Release ceremony (Lotodipine).jpg

 

Release ceremony (Starzine, Starzine).JPG

 

 

KyungDong Pharm held launch ceremonies on May 16 for Starzin Tablets and Stamezin Tablets, DPP-4 inhibitor treatments for type 2 diabetes, and on June 26 for Rotodipin Tablets, a treatment for dyslipidemia and hypertension. Starzin is a single-ingredient formulation containing sitagliptin 50 mg or 100 mg. Stamezin is an immediate-release combination of sitagliptin and metformin available in three strengths: 50/500 mg, 50/850 mg and 50/1000 mg. Given the high prevalence of complications and other chronic conditions in people with diabetes, the Starzin/Stamezin range offers prescribers different strengths to accommodate dose adjustment. Rotodipin combines rosuvastatin for dyslipidemia with amlodipine for hypertension in one tablet, helping patients with both conditions adhere to treatment through once-daily dosing. Available in 5/5 mg, 10/5 mg and 20/5 mg strengths, it allows dose adjustment according to the patient’s condition. This generic-based combination considers both affordability and convenience and is particularly suited to middle-aged and older patients and those requiring long-term treatment.